“Obviously it's important to have options when we're looking at the various tracers that we're using for evaluation of patients with prostate cancer,” says Brian F. Chapin, MD.
In this interview, Brian F. Chapin, MD, discusses the recent FDA approval of flotufolastat F 18 (Posluma) for prostate cancer. Chapin is an associate professor of urology at the University of Texas MD Anderson Cancer Center in Houston.
Please discuss the significance of the FDA approval of flotufolastat F 18 (Posluma) for prostate cancer.
Obviously it's important to have options when we're looking at the various tracers that we're using for evaluation of patients with prostate cancer. Currently, there are 2 that are being used within the US, and so this is somewhat US-specific as far as what's available. RH PSA 7.3 is a radiohybrid, so it is a different type of PSMA targeting agent that is now available for use for evaluation of patients as far as staging as well as for evaluating recurrence in those who've had biochemical recurrence after local therapy. Basically, the radiohybrid portion of this allows for this to be both diagnostic and hopefully in the future, therapeutic. So basically having the same agent that's being used for both diagnosis and for potential treatment when you're talking about things like a radioactive therapeutic like lutetium [Pluvicto].
This transcript was edited for clarity.